Metropolis Healthcare Reports 19% Drop in Q4 Net Profit

14 May 2025 , 10:59 AM

Metropolis Healthcare Ltd reported its Q4 FY25 numbers on May 13, with the net profit declining 19.4% year over year (YoY) to ₹29 crore from ₹36 crore in Q4 FY24. Revenues from operations of the company increased 4.3% YoY to ₹345.3 crore from ₹331 crore in the same quarter last year.

Even though the revenues had improved, EBITDA fell by 22% YoY from ₹80 crore to ₹62.3 crore due to increased operating costs or margin squeeze. The EBITDA margin fell to 18% in Q4 FY25 from 24.2% in Q4 FY24, reflecting a fall in operational efficiency or profitability.

Year on year, patient volume grew 6% year on year with consistent demand for diagnostic services in all markets. Test volume in FY25 increased 7% year-on-year, indicating growth in utilization of services and overall demand for tests. The revenue per patient increased 6% year-on-year with the help of scientific upselling and price strategies optimized for particular micro-markets.

The business-to-consumer (B2C) revenues of the company posted a 17% year-over-year (YoY) growth for the year since the retail diagnostics segment was the focus area. In Q4 FY25 alone, B2C revenue increased 14% YoY with the support of sustained investments in customer experience enhancement and service delivery network extension.

In the business-to-business (B2B) segment, Metropolis Healthcare posted a 12% year-over-year (YoY) growth in revenue during FY25 on account of improved quality of services and stronger interactions with partner networks. B2B revenue increased 10% YoY in the fourth quarter, again proving the consolidation of the company’s institutional ties.

The TruHealth diagnostics business of the company achieved a 24% year-over-year revenue growth in FY25 as awareness and demand for preventive health check-ups remained unrelenting. TruHealth contributed 19% to the company’s Q4 FY25 revenue, reflecting the increased contribution it makes to the overall performance of the company.

Specialty diagnostics business increased 13% YoY for the full year with consistent momentum in high-end as well as specialty test segments. Tier-III cities added 18% of revenue on a total basis in FY25, reflecting Metropolis’s successful strategy of deeper penetration into underpenetrated markets.

The diagnostics network increased its footprint to more than 750 towns in the financial year under review, hugely improving access to quality testing services. In FY25, the company added 29 new labs and 400 diagnostic centers, demonstrating a clear push towards building its infrastructure as well as last-mile delivery network.

In all, Metropolis Healthcare maintained to adhere to revenue growth plans, patient-focused initiatives, and growing its market base even though it faced margin pressure due to a decline in its quarterly profit.